Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Articles in E-pub version are posted online ahead of regular printed publication.

Correspondence

Correspondence: Response to Editorial on “Unveiling TRIB3: A New Mediator in MET-Driven Hepatocellular Carcinoma Progression”

Tiantian Wang, Wenjie Huang, Limin Xia

Received May 6, 2025 Accepted May 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0507 [Accepted]

View: 27 Download: 0

Reply to Correspondence

Advancing Metabolic Risk Profiling in Chronic Hepatitis B

Shang-Chin Huang, Jia-Horng Kao

Received May 4, 2025 Accepted May 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0500 [Accepted]

View: 28 Download: 2

Reply to correspondence on “A Novel Link Between Tumor Cell Metabolism and Patient Prognosis: Editorial on ‘Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway’”

Eun Ji Jang, Pil Soo Sung

Received May 3, 2025 Accepted May 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0498 [Accepted]

View: 27 Download: 1

Correspondence

Correspondence to editorial “Metabolic health in antiviral era of chronic hepatitis B”

Rui Huang, Mindie H. Nguyen

Received April 29, 2025 Accepted May 4, 2025

DOI: https://doi.org/10.3350/cmh.2025.0479 [Accepted]

View: 82 Download: 1

Research Letter

Contemporary Burden of Mortality from Chronic Liver Disease by Sex and Race/Ethnicity in the United States

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Received April 10, 2025 Accepted May 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0384 [Accepted]

View: 80 Download: 10

Correspondence

Correspondence to editorial “Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B”

Rui Huang, Mindie H. Nguyen

Received April 29, 2025 Accepted May 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0478 [Accepted]

View: 82 Download: 0

Correspondence to letter to the editor on “Risk Stratification of Metabolic Dysfunction-Associated Steatotic Liver Disease: The KASL Pathway

Hye Won Lee, Seung Up Kim

Received April 29, 2025 Accepted May 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0477 [Accepted]

View: 77 Download: 2

Research Letter

Non-infectivity of Hepatitis B Virus Under Nucleoside Analog Therapy Revealed Through Auxiliary Partial Orthotopic Liver Transplantation (APOLT)

Xiaojie Chen, Guiwen Guan, Lin Wei, Jidong Jia, Xiangmei Chen, Fengmin Lu, Zhijun Zhu

Received April 9, 2025 Accepted May 1, 2025

DOI: https://doi.org/10.3350/cmh.2025.0393 [Accepted]

View: 74 Download: 9

Letter to the Editor

Molecular Stratification of Hepatocellular Carcinoma by Metabolic-Signaling Pathways Guides Precision Immunotherapy and TACE Therapy

Binghua Li, Yanchao Xu, Yican Zhu, Yukun Zhang, Zijie Wu, Tianci Luo, Laizhu Zhang, Weiwei Hu, Decai Yu

Received March 27, 2025 Accepted April 29, 2025

DOI: https://doi.org/10.3350/cmh.2025.0344 [Accepted]

View: 88 Download: 8

Editorial

Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B

Heejoon Jang, Won Kim

Received April 16, 2025 Accepted April 25, 2025

DOI: https://doi.org/10.3350/cmh.2025.0430 [Accepted]

View: 143 Download: 12

Unveiling TRIB3: A New Mediator in MET-Driven Hepatocellular Carcinoma Progression

Many Sze Man CHAN, Terence Kin Wah LEE

Received April 23, 2025 Accepted April 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0452 [Accepted]

View: 164 Download: 16

Correspondence

Correspondence to editorial on “Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway.”

Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo

Received April 18, 2025 Accepted April 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0435 [Accepted]

View: 119 Download: 8

Editorial

RISK STRATIFICATION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: THE KASL PATHWAY

May Xuan GOH, Xin En GOH, Jarell Jie-Rae TAN, Vincent L CHEN, Yu Jun WONG

Received April 14, 2025 Accepted April 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0420 [Accepted]

View: 125 Download: 8

Reply to Correspondence

GULP1: New Hope for Hepatocellular Carcinoma: Reply to Correspondence on “GULP1 as a Novel Biomarker in HCC”

Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen

Received April 14, 2025 Accepted April 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0415 [Accepted]

View: 142 Download: 6

Correspondence

Correspondence to editorial “Targeting CD36 to reinvigorate CD8+ T Cells in early-stage hepatocellular carcinoma”

Yifei Qin, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu

Received April 11, 2025 Accepted April 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0402 [Accepted]

View: 193 Download: 13

Letter to the Editor

Letter “Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target”

Yuqian Liu, Ruiyun Guo, Jun Ma

Received April 6, 2025 Accepted April 21, 2025

DOI: https://doi.org/10.3350/cmh.2025.0377 [Accepted]

View: 198 Download: 18

Original Article

GLP-1 RA and Reduced Liver and Non-Liver Complications in Adults with T2D and MASLD: A Target Trial Emulation Study

Xianhua Mao, Xinrong Zhang, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H Nguyen

Received December 5, 2024 Accepted April 21, 2025

DOI: https://doi.org/10.3350/cmh.2024.1096 [Accepted]

View: 510 Download: 54

HTD1801 Demonstrates Promising Potential for Histologic Improvements in MASH in Both a Preclinical and Phase 2 Study

Vincent Wai-Sun Wong, Guy W. Neff, Adrian M. Di Bisceglie, Ru Bai, Junwei Cheng, Meng Yu, Alexander Liberman, Liping Liu, Nadege Gunn

Received February 8, 2025 Accepted April 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0145 [Accepted]

View: 359 Download: 24

Editorial

A Novel Link Between Tumor Cell Metabolism and Patient Prognosis: Editorial on “Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway”

Eun Ji Jang, Pil Soo Sung

Received April 9, 2025 Accepted April 14, 2025

DOI: https://doi.org/10.3350/cmh.2025.0395 [Accepted]

View: 172 Download: 8

Reply to Correspondence

Reply to authors’ reply: “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”

Mathias Jachs, Mattias Mandorfer

Received April 9, 2025 Accepted April 14, 2025

DOI: https://doi.org/10.3350/cmh.2025.0391 [Accepted]

View: 181 Download: 4

Review

Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunction-associated steatotic liver disease

Eiji Kakazu, Masaaki Mino, Tatsuya Kanto

Received January 14, 2025 Accepted April 12, 2025

DOI: https://doi.org/10.3350/cmh.2025.0048 [Accepted]

View: 604 Download: 91

Correspondence

Correspondence to Editorial on “Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial”

Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang

Received April 7, 2025 Accepted April 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0379 [Accepted]

View: 156 Download: 8

Original Article

Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States

Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D. Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q. Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G. Singal, Ju Dong Yang

Received February 12, 2025 Accepted April 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0169 [Accepted]

View: 843 Download: 53

MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation

Tiantian Wang, Dean Rao, Chenan Fu, Zhoubin Sun, Yiming Luo, Junli Lu, Jie Jin, Han Li, Feimu Fan, Huifang Liang, Wenjie Huang, Limin Xia

Received December 24, 2024 Accepted April 8, 2025

DOI: https://doi.org/10.3350/cmh.2024.1163 [Accepted]

View: 755 Download: 99

Editorial

Metabolic Health in Antiviral Era of Chronic Hepatitis B

Shang-Chin Huang, Jia-Horng Kao

Received April 3, 2025 Accepted April 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0369 [Accepted]

View: 203 Download: 17

Viral manipulation of host cell glutamine metabolism and glutamine rewiring in hepatic diseases: Editorial on “GDH1-dependent α-ketoglutarate promotes HBV transcription by modulating histone methylations on the cccDNA minichromosome”

Mehrangiz Dezhbord, Kyun-Hwan Kim

Received April 2, 2025 Accepted April 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0366 [Accepted]

View: 228 Download: 38

Correspondence

Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients

Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu

Received April 2, 2025 Accepted April 2, 2025

DOI: https://doi.org/10.3350/cmh.2025.0362 [Accepted]

View: 323 Download: 12

Original Article

Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease

Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim

Received December 30, 2024 Accepted April 2, 2025

DOI: https://doi.org/10.3350/cmh.2024.1183 [Accepted]

View: 432 Download: 55

Correspondence

Correspondence: Response to Editorial on “GULP1, a Multifaceted Biomarker and Therapeutic Target in HCC”

Soon Sun Kim, Hyung Seok Kim, Jae Youn Cheong, Jung Woo Eun

Received March 28, 2025 Accepted April 2, 2025

DOI: https://doi.org/10.3350/cmh.2025.0350 [Accepted]

View: 216 Download: 6

Research Letter

Lipidomic analysis of alcohol use disorder patients revealed the biomarkers for alcohol-related liver disease susceptibility

Dongyao Wang, Hongwei Zhang, Yuxiao Tang

Received February 26, 2025 Accepted March 30, 2025

DOI: https://doi.org/10.3350/cmh.2025.0227 [Accepted]

View: 297 Download: 30

Review

Emerging Therapies and Real-World Application of Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment

Hee Yeon Kim, Mary E. Rinella

Received January 22, 2025 Accepted March 30, 2025

DOI: https://doi.org/10.3350/cmh.2025.0083 [Accepted]

View: 800 Download: 109

Editorial

Targeting CD36 to reinvigorate CD8+ T Cells in early-stage hepatocellular carcinoma

Valerie Chew

Received March 25, 2025 Accepted March 28, 2025

DOI: https://doi.org/10.3350/cmh.2025.0334 [Accepted]

View: 381 Download: 31

Correspondence

Correspondence to editorial 3 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”

Haiyu Wang, Jinjun Chen

Received March 23, 2025 Accepted March 28, 2025

DOI: https://doi.org/10.3350/cmh.2025.0328 [Accepted]

View: 219 Download: 4

Correspondence to editorial 2 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”

Haiyu Wang, Jinjun Chen

Received March 23, 2025 Accepted March 28, 2025

DOI: https://doi.org/10.3350/cmh.2025.0327 [Accepted]

View: 219 Download: 3

Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”

Haiyu Wang, Jinjun Chen

Received March 23, 2025 Accepted March 28, 2025

DOI: https://doi.org/10.3350/cmh.2025.0326 [Accepted]

View: 247 Download: 9

Review

Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury – chronic kidney disease spectrum

Vishnu Girish, Rakhi Maiwall

Received November 24, 2024 Accepted March 24, 2025

DOI: https://doi.org/10.3350/cmh.2024.1060 [Accepted]

View: 636 Download: 102

Editorial

GULP1, A Multifaceted Diagnostic Biomarker and Potential Therapeutic Target in Hepatocellular Carcinoma: Editorial on “GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma”

Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen

Received March 18, 2025 Accepted March 21, 2025

DOI: https://doi.org/10.3350/cmh.2025.0315 [Accepted]

View: 284 Download: 21

Besifovir: a viable option for long-term disease control in chronic hepatitis B

Wai-Kay Seto

Received March 15, 2025 Accepted March 20, 2025

DOI: https://doi.org/10.3350/cmh.2025.0305 [Accepted]

View: 195 Download: 11

Refining Portal Hypertension Assessment: The Clinical Significance of Spleen Stiffness Measurement in the Baveno VII Era

Do Seon Song

Received March 13, 2025 Accepted March 20, 2025

DOI: https://doi.org/10.3350/cmh.2025.0296 [Accepted]

View: 228 Download: 24

Letter to the Editor

Letter “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”

Qiong Wang, Zhongqing Qian, Xiaodi Yang, Deyan Chen, Xiaojing Wang, Fuliang Chen

Received March 13, 2025 Accepted March 19, 2025

DOI: https://doi.org/10.3350/cmh.2025.0291 [Accepted]

View: 251 Download: 14

Correspondence

Correspondence: Response to the Letter Regarding "GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma"

Hyung Seok Kim, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun

Received March 12, 2025 Accepted March 15, 2025

DOI: https://doi.org/10.3350/cmh.2025.0287 [Accepted]

View: 381 Download: 24

Editorial

Unveiling GULP1 as a Hepatocyte-Specific Role for Recurrence: Editorial on “GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma”

Pengde Lu, Ning Wang

Received March 11, 2025 Accepted March 15, 2025

DOI: https://doi.org/10.3350/cmh.2025.0282 [Accepted]

View: 307 Download: 20

A non-invasive risk stratification tool for hepatitis B-related liver cirrhosis: the Baveno VI-SSM combined model.

Ruiling He, Bingtian Dong, Xiaolong Qi

Received March 11, 2025 Accepted March 15, 2025

DOI: https://doi.org/10.3350/cmh.2025.0281 [Accepted]

View: 339 Download: 26

Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?

Mathias Jachs, Mattias Mandorfer

Received March 11, 2025 Accepted March 15, 2025

DOI: https://doi.org/10.3350/cmh.2025.0280 [Accepted]

View: 300 Download: 24

The Evolution of Non-Invasive Strategies in Cirrhosis Management—From Screening to Precision Monitoring：Editorial on ‘FIB-4plus Score: A novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): An international multicenter study’

Haiyu Wang, Jinjun Chen

Received March 9, 2025 Accepted March 15, 2025

DOI: https://doi.org/10.3350/cmh.2025.0274 [Accepted]

View: 298 Download: 15

Original Article

Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatment

Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Atsukawa, Hirokazu Takahashi, Kunihiko Tsuji, Koichi Takaguchi, Pei-Chien Tsai, Chia-Yen Dai, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Eileen Yoon, Sung Eun Kim, Sang Bong Ahn, Gi-Ae Kim, Jang Han Jung, Soung Won Jeong, Hyunwoo Oh, Cheng-Hao Tseng, Masatoshi Ishigami, Angela Chau, Mayumi Maeda, Satoshi Yasuda, Makoto Chuma, Takanori Ito, Keigo Kawashima, Joanne Kimiko Liu, Adrian Gadano, Ritsuzo Kozuka, Norio Itokawa, Kaori Inoue, Tomonori Senoh, Jie Li, Wan-Long Chuang, Ramsey Cheung, Chao Wu, Ming-Lung Yu, Mindie H. Nguyen

Received November 27, 2024 Accepted March 14, 2025

DOI: https://doi.org/10.3350/cmh.2024.1070 [Accepted]

View: 1099 Download: 90

Letter to the Editor

Critical Considerations in Evaluating the Therapeutic Potential of HK-660S for Primary Sclerosing Cholangitis

He Yizi, He Haifeng, Liang Qi, Xie Yongzhi

Received March 1, 2025 Accepted March 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0239 [Accepted]

View: 246 Download: 19

Reply to Correspondence

SHOULD DIRECT-ACTING ANTIVIRAL BE CONSIDERED FOR ALL PATIENTS WITH HCV-RELATED HEPATOCELLULAR CARCINOMA?

Yan Ling ONG, Apichat KAEWDECH, Yu Jun WONG

Received March 5, 2025 Accepted March 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0257 [Accepted]

View: 271 Download: 11

Editorial

Modulation of PRL-1 in Placental MSCs: A Novel Therapeutic Strategy for Hepatic Fibrosis: Editorial on “Modulation of PRL-1 within placental MSCs instigates the transition between EMT and MET subsequent to hepatic fibrosis”

Lihai Jiang, Wenjie Zheng

Received March 5, 2025 Accepted March 9, 2025

DOI: https://doi.org/10.3350/cmh.2025.0264 [Accepted]

View: 253 Download: 13

Regulation of Hepatitis B Virus cccDNA by Metabolic Pathways

Hyeong-Jin Cho, Sung-Gyoo Park

Received March 4, 2025 Accepted March 9, 2025

DOI: https://doi.org/10.3350/cmh.2025.0255 [Accepted]

View: 390 Download: 43

Original Article

Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway

Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, Kazuko Sakai, Naoto Fujiwara, Masakatsu Tsurusaki, Kohei Hanaoka, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Atsushi Takebe, Takaaki Murase, Keiko Kamei, Takuya Nakai, Ippei Matsumoto, Kazuto Nishio, Masatoshi Kudo

Received December 3, 2024 Accepted March 7, 2025

DOI: https://doi.org/10.3350/cmh.2024.1088 [Accepted]

View: 1200 Download: 143

Letter to the Editor

Letter to the Editor on “Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023”

Sisi Yang, Zhenxuan Ma

Received February 11, 2025 Accepted March 6, 2025

DOI: https://doi.org/10.3350/cmh.2025.0153 [Accepted]

View: 304 Download: 19

Letter “GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma”

Juan Yang, Xinyi Li, Sheng Zheng

Received February 24, 2025 Accepted March 5, 2025

DOI: https://doi.org/10.3350/cmh.2025.0216 [Accepted]

View: 383 Download: 40

Correspondence

Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage

Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu

Received February 28, 2025 Accepted March 1, 2025

DOI: https://doi.org/10.3350/cmh.2025.0235 [Accepted]

View: 469 Download: 18

Research Letter

Mendelian randomization does not support the effects of G-CSF on decompensated liver disease

Li Liling, Wang Hui, Wang Hong, Huang Jinchang

Received February 27, 2025 Accepted March 1, 2025

DOI: https://doi.org/10.3350/cmh.2025.0172 [Accepted]

View: 380 Download: 35

Original Article

CD36 Promotes Iron Accumulation and Dysfunction in CD8⁺ T Cells via the p38-CEBPB-TfR1 Axis in Early-stage Hepatocellular Carcinoma

Yifei Qin, Fei Huo, Zhuan Feng, Jialu Hou, Yaxin Ding, Quancheng Wang, Yu Gui, Ziwei Yang, Jiali Yang, Gang Zhou, Ling Li, Jianli Jiang, Lingmin Kong, Shijie Wang, Gang Nan, Dingqiao Xu, Xiaohang Xie, Lijuan Wang, Qian He, Ruibin Yang, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu

Received November 3, 2024 Accepted March 1, 2025

DOI: https://doi.org/10.3350/cmh.2024.0948 [Accepted]

View: 1029 Download: 199

Special Review

Liver Disease Trends in the Asia-Pacific Region for the Next 50 Years

Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim

Received January 15, 2025 Accepted February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0043 [Accepted]

View: 571 Download: 53

Letter to the Editor

Re: "Bariatric Surgery Reduces Long-Term Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Cirrhosis"

Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou

Received February 18, 2025 Accepted February 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0189 [Accepted]

View: 568 Download: 47

Correspondence

HCC predictors in routine practice for patients with chronic liver diseases

Tung-Hung Su, Jia-Horng Kao

Received February 18, 2025 Accepted February 22, 2025

DOI: https://doi.org/10.3350/cmh.2025.0187 [Accepted]

View: 254 Download: 6

Editorial

Direct-acting antiviral attained sustained virological response improve overall survival in patients with HCV-related hepatocellular carcinoma

Yan Ling Ong, Apichat Kaewdech, Daniel Q Huang, Yu Jun Wong

Received February 14, 2025 Accepted February 21, 2025

DOI: https://doi.org/10.3350/cmh.2025.0174 [Accepted]

View: 396 Download: 27

Letter to the Editor

Classification of microvascular invasion of hepatocellular carcinoma: different standards, common goals

Wei Chen, Yihui Rong, Tianshi Ma, Weiwei Shi, Wei Chen, Hang Jiang

Received February 11, 2025 Accepted February 14, 2025

DOI: https://doi.org/10.3350/cmh.2025.0167 [Accepted]

View: 365 Download: 39

Editorial

Can SAFE score be utilized as a universal hepatocellular carcinoma prediction score? Editorial on “High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease”

Michael Kwan-Lung Ko, Loey Lung-Yi Mak

Received February 3, 2025 Accepted February 7, 2025

DOI: https://doi.org/10.3350/cmh.2025.0118 [Accepted]

View: 309 Download: 18

Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease

Ho Soo Chun, Minjong Lee

Received February 2, 2025 Accepted February 7, 2025

DOI: https://doi.org/10.3350/cmh.2025.0116 [Accepted]

View: 355 Download: 18

Original Article

Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target

Gu-Wei Ji, Zheng-Gang Xu, Shuo-Chen Liu, Shu-Ya Cao, Chen-Yu Jiao, Ming Lu, Biao Zhang, Yue Yang, Qing Xu, Xiao-Feng Wu, Ke Wang, Yong-Xiang Xia, Xiang-Cheng Li, Xue-Hao Wang

Received October 9, 2024 Accepted February 7, 2025

DOI: https://doi.org/10.3350/cmh.2024.0895 [Accepted]

View: 6619 Download: 251

GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma

Hyung Seok Kim, Jung Hwan Yoon, Ji Yi Choi, Moon Gyeong Yoon, Geum Ok Baek, Minji Kang, Se Ha Jang, Won Park, Yunjin Go, Jestlin Tianthing Ng, Suk Woo Nam, Jee-Yeong Jeong, Ji Eun Han, Hyo Jung Cho, Su Bin Lim, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun

Received November 19, 2024 Accepted February 4, 2025

DOI: https://doi.org/10.3350/cmh.2024.1038 [Accepted]

View: 2295 Download: 632 Crossref: 1

Letter to the Editor

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Chi-Kuei Hsu, Po-Yu Huang, Chih-Cheng Lai

Received January 19, 2025 Accepted February 4, 2025

DOI: https://doi.org/10.3350/cmh.2025.0073 [Accepted]

View: 356 Download: 25

Snapshot

Interventions Targeting the Gut-Liver Axis: A Potential Treatment Strategy for MASLD

Pingping Jin, Xinyi Lu, Daozhen Chen, Yu Chen

Received December 2, 2024 Accepted February 4, 2025

DOI: https://doi.org/10.3350/cmh.2024.1090 [Accepted]

View: 511 Download: 81

Original Article

Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study

Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bair, Te-Sheng Chang, Chun-Yen Lin, Szu-Jen Wang, Tsai-Yuan Hsieh, Tzeng-Hue Yang, Cheng-Yuan Peng, Chi-Chieh Yang, Lee-Won Chong, Chien-Wei Huang, Chih-Wen Lin, Cheng-Hsin Chu, Ming-Chang Tsai, Jia-Horng Kao, Chun-Jen Liu, Wan-Long Chuang, Teng-Yu Lee, Ming- Lung Yu, on behalf of TACR investigators

Received November 10, 2024 Accepted January 16, 2025

DOI: https://doi.org/10.3350/cmh.2024.1015 [Accepted]

View: 1449 Download: 108

FIB-4plus Score: A novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): An international multicenter study

Bingtian Dong, Ruiling He, Shenghong Ju, Yuping Chen, Ivica Grgurevic, Jianzhong Ma, Ying Guo, Huizhen Fan, Qiang Yan, Chuan Liu, Huixiong Xu, Anita Madir, Kristian Podrug, Jia Wang, Linxue Qian, Zhengzi Geng, Shanghao Liu, Tao Ren, Guo Zhang, Kun Wang, Meiqin Su, Fei Chen, Sumei Ma, Liting Zhang, Zhaowei Tong, Yonghe Zhou, Xin Li, Fanbin He, Hui Huan, Wenjuan Wang, Yunxiao Liang, Juan Tang, Fang Ai, Tingyu Wang, Liyun Zheng, Zhongwei Zhao, Jiansong Ji, Wei Liu, Jiaojiao Xu, Bo Liu, Xuemei Wang, Yao Zhang, Qiong Yan, Hui Liu, Xiaomei Chen, Shuhua Zhang, Yihua Wang, Yang Liu, Li Yin, Yanni Liu, Yanqing Huang, Li Bian, Ping An, Xin Zhang, Shaoting Zhang, Jinhua Shao, Xiangman Zhang, Wei Rao, Chaoxue Zhang, Christoph Frank Dietrich, Won Kim, Xiaolong Qi

Received October 10, 2024 Accepted February 3, 2025

DOI: https://doi.org/10.3350/cmh.2024.0898 [Accepted]

View: 1715 Download: 150

Review

Deciphering adenosine signaling in hepatocellular carcinoma: pathways, prognostic models, and therapeutic implications

Huihai Yang, Martina Mang Leng Lei, Longfei Xie, Yinuo Shou, Terence Kin Wah Lee

Received November 26, 2024 Accepted February 2, 2025

DOI: https://doi.org/10.3350/cmh.2024.1068 [Accepted]

View: 1177 Download: 117

Original Article

Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis

Haiyu Wang, Weihao Liang, Ling Zhou, Jiankang Song, Biao Wen, Qiaoping Wu, Yuanjian Zhang, Xiaofeng Zhang, Haoran Ke, Yujun Tang, Fuyuan Zhou, Youfu Zhu, Weiqun Wen, Zhihua Liu, Yali Ji, Qintao Lai, Qinjun He, Wenfan Luo, Tingting Qi, Miaoxia Liu, Xiaoqin Lan, Yongpeng Chen, Ranran Xi, Junting Wan, Lin Dai, Yuan Li, Jinjun Chen

Received July 29, 2024 Accepted January 29, 2025

DOI: https://doi.org/10.3350/cmh.2024.0609 [Accepted]

View: 782 Download: 100

GDH1-dependent α-ketoglutarate promotes HBV transcription by modulating histone methylations on the cccDNA minichromosome

Sheng-Tao Cheng, Wei-Xian Chen, Hai-Jun Deng, Xin He, Hui Zhang, Ming Tan, Hai-Bo Yu, Zhen-Zhen Zhang, Ji-Hua Ren, Min-Li Yang, Da-Peng Zhang, Zhi-Hong Li, Juan Chen

Received August 21, 2024 Accepted January 28, 2025

DOI: https://doi.org/10.3350/cmh.2024.0694 [Accepted]

View: 1100 Download: 213

Review

Unveiling the Intratumor Microbiome in Liver Cancer: Current Insights and Prospective Applications

Xindi Ke, Shangze Jiang, Qiaoxin Wei, Minghao Sun, Hang Sun, Mingchang Pang, Mei Liu, Lejia Sun, Huayu Yang, Yilei Mao

Received November 19, 2024 Accepted January 20, 2025

DOI: https://doi.org/10.3350/cmh.2024.1039 [Accepted]

View: 1078 Download: 145 Crossref: 1

Original Article

Modulation of PRL-1 within placental MSCs instigates the transition between EMT and MET subsequent to hepatic fibrosis

Jae Yeon Kim, Hyeri Park, Soo Young Park, Se Ho Kim, Ja Yun Lim, Ki Seog Lee, Si Hyun Bae, Gi Jin Kim

Received September 12, 2024 Accepted January 20, 2025

DOI: https://doi.org/10.3350/cmh.2024.0741 [Accepted]

View: 4263 Download: 765

Letter to the Editor

What is new in the 2024 Chinese guidelines for fatty liver disease?

Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan

Received December 27, 2024 Accepted January 18, 2025

DOI: https://doi.org/10.3350/cmh.2024.1165 [Accepted]

View: 445 Download: 43

Original Article

Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial

Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Woong Lee, Jung Hyun Kwon, Moon Young Kim, Do Seon Song, Jung Gil Park, Yoon Seok Lee, Eileen L. Yoon, Han Ah Lee, Seong Hee Kang, Jin Mo Yang

Received September 19, 2024 Accepted January 16, 2025

DOI: https://doi.org/10.3350/cmh.2024.0819 [Accepted]

View: 1501 Download: 72

High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease

Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, Wei-Yu Kao, Shang-Chin Huang, Fen-Fang Chen, Francis SK Poon, Lung-Wen Tsai, Yi-Ting Chen, Che Lin, Weichung Wang, W Ray Kim, Jia-Horng Kao

Received September 21, 2024 Accepted January 1, 2025

DOI: https://doi.org/10.3350/cmh.2024.0822 [Accepted]

View: 1226 Download: 125

Letter to the Editor

Current Burden of MASLD, MetALD, and Hepatic Fibrosis among US Adults with Prediabetes and Diabetes, 2017-2023

Donghee Kim, Rohit Loomba, Aijaz Ahmed

Received December 20, 2024 Accepted December 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.1150 [Accepted]

View: 1256 Download: 154

Original Article

Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in acute liver failure

Neha Sharma, Sushmita Pandey, Gaurav Tripathi, Manisha Yadav, Nupur Sharma, Babu Mathew, Abhishak Gupta, Vasundhra Bindal, Sadam H. Bhat, Yash magar, Rimsha Saif, Sanju Yadav, Amritpal Kaur, Rakhi Maiwall, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras

Received July 12, 2024 Accepted December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0554 [Accepted]

View: 2588 Download: 107

Viewed By 10152	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7215	MAFLD: How is it different from NAFLD?
Viewed By 5205	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4700	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4650	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 322	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 304	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 208	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 103	Non-alcoholic fatty liver disease: Definition and subtypes

Ahead-of-print